Clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China: A hospital-based retrospective study

Japanese Journal of Infectious Diseases

Volumn 68, Issue 3, 2015, Pages 244-247

  Liu, Yu ^a   Bao, Pengtao ^a   Wang, Di ^a   Li, Yun ^a   Tang, Liping ^a   Zhou, Yi ^a   Zhao, Weiguo ^a  

^a 309TH HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM HYDROXIDE; HYPOCHLORITE SODIUM; PLATELET RICH FIBRIN; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG; LINEZOLID; TUBERCULOSTATIC AGENT;

ADOLESCENT; ARTICLE; BLEEDING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ENDODONTICS; FOLLOW UP; HUMAN; INCISOR; INFRABONY DEFECT; MALE; PHOTODYNAMIC THERAPY; RADIOGRAPHY; TOOTH DISEASE; ADULT; CHINA; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; CHINA; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; LINEZOLID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929401491     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.JJID.2014.222     Document Type: Article

References (16)

1. World Health Organization. Anti-Tuberculosis Drug Resistance in the World. In report no. 4. Geneva: WHO; 2008.
2. Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med. 2008;178:1180-5.
3. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2010;50:49-55.
4. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug resistant tuberculosis. N Engl J Med. 2012;367:1508-18.
5. Wang D, Zhu X, Cui C, et al. Discovery of novel acetohydroxyacid synthase inhibitors as in vitro active agents against Mycobacterium tuberculosis by virtual screening and bioassay. J Chem Inf Model. 2013;53:343-53.
6. Wang D, Pan L, Cao G, et al. Evaluation of the in vitro and intracellular efficacy of new monosubstituted sulfonylureas against extensively drug-resistant tuberculosis. Int J Antimicrob Agents
7. Narita M, Tsuji T, Yu V. Linezolid-associated peripheral and optic neuropathy, lacticacidosis, and serotonin syndrome. Pharmacotherapy. 2007;27:1189-97.
8. Rubinstein E, Isturiz R, Standiford H, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparatorcontrolled phase III studies. Antimicrob Agents Chemother. 2003;47:1824-31.
9. World Health Oranization. 2009 Update Tuberculosis Facts. Geneva:WHO; 2009.
10. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006;81: 430-2.
11. Punga VV, Jakubowiak WM, Danilova ID, et al. Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia. Int J Tuberc Lung Dis. 2009;13:1309-12.
12. Brown H. WHO identifies drug-resistant tuberculosis ``hotspots''. Former Russian states are worst affected, but lack of data from China hides true extent of disease. Lancet. 2004;363:951.
13. Park I, Hong S, Oh Y, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant TB. J Antimicrob Chemother. 2006;58:701-4.
14. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant TB. J Antimicrob Chemother. 2005;56:180-5.
15. Xu H-B, Jiang R-H, Li L, et al. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis. 2012;16:358-63.
16. Yang CE, Lei H, Wang D, et al. In vitro activity of linezolid against clinical Isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains isolated from Beijing, China. Jpn J Infect Dis. 2012;65:240-2.